Alterity reveals positive Phase 2 results for ATH434 in Multiple System Atrophy

Alterity Therapeutics has disclosed results from its Phase 2 ATH434-201 clinical trial in patients with Multiple System Atrophy (MSA), according to the company. The randomized, double-blind, placebo-controlled study evaluated two doses of ATH434 (50 mg and 75 mg twice daily) over 12 months in 77 adu…